Exalenz Bioscience provides Gastroenterologists, General Practice Physicians and Hepatologists advanced tools for diagnosing and managing a wide range of conditions in the fields of liver health and gastroenterology.
The BreathID® system is an advanced technology platform used to assess a range of liver and gastrointestinal disorders via molecular analysis of the patient’s exhaled breath. The system is the only breath-testing technology with the ability to provide continuous, automatic, real-time patient monitoring and data analysis and deliver immediate results. BreathID-based products use a clinically proven, sophisticated laser-like light source to pinpoint real-time changes in 13C/12C isotope ratios at an accuracy level of single parts per million.
The company’s stock is traded on the Tel Aviv Stock Exchange (TASE), under the EXEN ticker symbol.
In the US, the BreathID® Hp System and the BreathID® Hp Lab System are intended for use in the qualitative detection of H. pylori. They have FDA 510(k) clearance and an approved NDA for the 13C-urea tablet and Citrica powder.
Code of Ethics and Business Conduct
Hadas Fridman | KM Investor Relations Ltd.